

Special Issue

Past, Present and Future Radiotracer Techniques: Radiopharmaceuticals in Cancer Theranostics

Message from the Guest Editors

More than five years ago, [^{177}Lu]Lu-DOTA-TATE (Lutathera®) was approved for Peptide Receptor Radionuclide Therapy (PRRT) of neuroendocrine tumors (NET) while joining its diagnostic counter-partner [^{68}Ga]Ga-DOTA-TOC. A further success story was represented by the approval of [^{177}Lu]Lu-PSMA-617 (Pluvicto®) to various diagnostic counter-partners for the treatment of prostate cancer. However, the aforementioned theranostic pairs can only supply a limited number of cancer patients and, therefore, the development of new radiotracers and/or radiopharmaceuticals is further ongoing. All these essential steps can be covered in the Special Issue. Areas of interest include, but are not limited to:

- Development and pre-clinical evaluation of diagnostic tracers and radiotherapeutic pharmaceuticals
- Establishment and validation of GMP compliant synthesis and quality control
- Translation into clinics: first-in-human studies, clinical trials

Guest Editors

Dr. Ute Hennrich

Service Unit Radiopharmaceuticals and Pre-Clinical Studies, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 223, 69120 Heidelberg, Germany.

Dr. Martina Benešová-Schäfer

Research Group Molecular Biology of Systemic Radiotherapy, Research Program Imaging and Radiooncology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 223, 69120 Heidelberg, Germany

Deadline for manuscript submissions

closed (15 May 2025)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/178735

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)